Zacks.com on MSN2d
Merck Loses Almost $52B in 6 Months: How to Play MRK StockWe believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...
We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Jimmy Investor. In this article, we will summarize ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of ...
Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback